Skip to main content
Premium Trial:

Request an Annual Quote

Exon Skipping Restores Protein in Model of Duchenne Muscular Dystrophy

In a new study in Proceedings of the National Academy of Sciences, researchers from Ludwig Maximilian University of Munich describe their exon skipping analyses within a pig model of Duchenne muscular dystrophy (DMD) lacking DMD exon 52. DMD is caused by mutations in the DMD gene, which lead to the absence of dystrophin and eventually cause progressive degeneration of skeletal musculature and myocardium. While previous studies had led to experimental therapeutic approaches aimed at correcting the reading frame of the DMD gene, they were limited in its ability to completely restore dystrophin in all cardiomyocytes. "Thus, there is a need for DMD animal models that predict the best possible therapeutic outcome of exon skipping strategies," the authors write. In their paper, the authors find that in DMD patients and in a corresponding pig model, an additional deletion of DMD exon 51 alongside the deletion of DMD exon 52 leads to the expression of an internally shortened dystrophin, as the transcript is reframed. This presence of dystrophin was confirmed by immunohistochemistry, western blot analyses, and mass spectrometry.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.